GH - ゲノミック・ヘルス (Guardant Health Inc.) ゲノミック・ヘルス

 GHのチャート


 GHの企業情報

symbol GH
会社名 Genomic Health Inc (ゲノミック・ヘルス)
分野(sector)   
産業(industry)   
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Guardant Health Inc. is a United States-based company that engages in non-invasive cancer genomic sequencing. The Company is focused on developing diagnostic technologies that can transform cancer from a silent killer into a manageable disease. The Company engages in next-generation sequencing single-cell genomics and cancer diagnostics. The Company offers Guardant360 which is a biopsy-free tumor sequencing test that tracks tumor genomics in real-time and identifies associated treatment options. The 73-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases and interrogates all four types of genomic alterations. The test prevents repeat invasive biopsies when cancer has progressed or recurred despite treatment or when an initial biopsy is unobtainable or has insufficient tissue. It is the circulating tumor DNA (ctDNA) test that includes all somatic genomic targets in a single test.   ゲノミック・ヘルスは米国でがんの個別化治療のためのゲノム解析(遺伝子検査)を行う。侵潤性乳がん、結腸がん、前立腺がん用の腫瘍の大きさ、悪性度、再発性、化学療法の効果性などの情報を提供するオンコタイプDX検査を行う。また、他のがんに対するオンコタイプDX検査の臨床研究を行う。   Guardant Health, Inc. is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Redwood City, CA.
本社所在地 301 Penobscot Drive Redwood City CA 94063 USA
代表者氏名 AmirAli Talasaz アミアリタラサス
代表者役職名 President Chief Operating Officer Director
電話番号 +1 650-290-7575
設立年月日 36739
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 863人
url www.genomichealth.com
nasdaq_url https://www.nasdaq.com/symbol/gh
adr_tso
EBITDA EBITDA(百万ドル) ー
終値(lastsale) 29.55
時価総額(marketcap) 0
時価総額 時価総額(百万ドル) 357.621
売上高 売上高(百万ドル) --
企業価値(EV) 企業価値(EV)(百万ドル) 3294.422
当期純利益 当期純利益(百万ドル) --
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Guardant Health Inc revenues increased 93% to $36.1M. Net loss applicable to common stockholders decreased 13% to $35.5M. Revenues reflect United States segment increase of 77% to $29.5M International segment increase from $2.1M to $6.6M. Lower net loss reflects G/L on early Exting of lease relat debt decrease from $5.1M (expense) to $0K Interest Exp-Net of Capitalized Interest decrease of 69% to $648K (expense).

 GHのテクニカル分析


 GHのニュース

   SoftBank returns to profit after record losses  2020/08/11 09:13:43 Economic Times India
By Pavel AlpeyevSoftBank Group Corp. rebounded from a record loss to post a first-quarter profit as valuations for technology startups recovered from the coronavirus pandemic.Net income hit 1.26 trillion yen ($11.8 billion) for the three months ended June 30, the Tokyo-based company said in a statement on Tuesday, compared with a loss of 1.44 trillion yen three months earlier. The Vision Fund income was 129.6 billion yen, following a 1.13 trillion yen loss in the previous quarter.Masayoshi Son has pulled off a remarkably speedy comeback after the worst loss in his company’s 39-year history. A global rally in technology shares lifted the value of SoftBank’s stakes in publicly traded firms like Uber Technologies Inc. and improved the prospects for startups in its portfolio, from China’s Didi Chuxing to South Korea’s Coupang. Son also sold off assets and bought back shares at unprecedented rates, pushing up SoftBank’s own stock price to the highest in two decades.“There is a real case for increasing valuations at the Vision Fund, given how much the overall tech markets have rallied,” Justin Tang, head of Asian research at United First Partners in Singapore, said ahead of the announcement. “There are still a lot of caveats.”The $100 billion Vision Fund Son set up three years ago to invest in technology companies has become a key driver of SoftBank’s income.
   Première biopsie liquide à recevoir l'approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.  2020/08/08 12:24:00 PR Newswire
SINGAPOUR, 8 août 2020 /PRNewswire/ -- La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le profilage des mutations tumorales chez les patients atteints de toutes sortes de cancers solides….
   First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.  2020/08/07 19:01:00 PR Newswire
SINGAPORE, Aug. 7, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Guardant Health's liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval…
   Guardant Health Reports Second Quarter 2020 Financial Results  2020/08/06 20:03:00 GlobeNewswire
Q2 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a…
   Fund manager Tom O'Halloran quadrupled investors' money in 9 years by betting on super high-growth companies. He explained his approach, and why new technologies could make the next decade for markets even better than the 2010s.  2020/08/04 12:03:00 Business Insider
Thomas O'Halloran manages the Lord Abbett Growth Leaders Fund , which has more than quadrupled investors' money in nine years by investing in high-growth tech, consumer, and healthcare stocks. He's even more optimistic about the coming decade, reasoning that the combination of the "technology revolution" and low interest rates should keep a secular bull market going through 2030. He also says there's little reason to worry about the market dominance of Big Tech because companies like Microsoft and Amazon are innovating in ways that help other companies succeed. Click here to sign up for our weekly newsletter Investing Insider . Visit Business Insider's homepage for more stories . A lot of experts go back and forth between praising Big Tech and worrying that it is dangerously dominant — but Thomas O'Halloran is consistent in thinking the companies deserve their success. "These companies are the greatest companies the planet has ever seen," he said of Apple , Microsoft , Amazon , Alphabet , and Facebook . "I don't worry about it at all, the concentration.
   SoftBank returns to profit after record losses  2020/08/11 09:13:43 Economic Times India
By Pavel AlpeyevSoftBank Group Corp. rebounded from a record loss to post a first-quarter profit as valuations for technology startups recovered from the coronavirus pandemic.Net income hit 1.26 trillion yen ($11.8 billion) for the three months ended June 30, the Tokyo-based company said in a statement on Tuesday, compared with a loss of 1.44 trillion yen three months earlier. The Vision Fund income was 129.6 billion yen, following a 1.13 trillion yen loss in the previous quarter.Masayoshi Son has pulled off a remarkably speedy comeback after the worst loss in his company’s 39-year history. A global rally in technology shares lifted the value of SoftBank’s stakes in publicly traded firms like Uber Technologies Inc. and improved the prospects for startups in its portfolio, from China’s Didi Chuxing to South Korea’s Coupang. Son also sold off assets and bought back shares at unprecedented rates, pushing up SoftBank’s own stock price to the highest in two decades.“There is a real case for increasing valuations at the Vision Fund, given how much the overall tech markets have rallied,” Justin Tang, head of Asian research at United First Partners in Singapore, said ahead of the announcement. “There are still a lot of caveats.”The $100 billion Vision Fund Son set up three years ago to invest in technology companies has become a key driver of SoftBank’s income.
   Première biopsie liquide à recevoir l'approbation de la FDA pour le profilage complet des tumeurs dans tous les cancers solides, le diagnostic compagnon Guardant360® de Guardant Health gagne en crédibilité auprès des oncologues en Asie, au Moyen-Orient et en Afrique.  2020/08/08 12:24:00 PR Newswire
SINGAPOUR, 8 août 2020 /PRNewswire/ -- La Food and Drug Administration (FDA) des États-Unis a approuvé la biopsie liquide de Guardant Health, le diagnostic compagnon Guardant360®, pour le profilage des mutations tumorales chez les patients atteints de toutes sortes de cancers solides….
   First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.  2020/08/07 19:01:00 PR Newswire
SINGAPORE, Aug. 7, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Guardant Health's liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval…
   Guardant Health Reports Second Quarter 2020 Financial Results  2020/08/06 20:03:00 GlobeNewswire
Q2 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a…
   Fund manager Tom O'Halloran quadrupled investors' money in 9 years by betting on super high-growth companies. He explained his approach, and why new technologies could make the next decade for markets even better than the 2010s.  2020/08/04 12:03:00 Business Insider
Thomas O'Halloran manages the Lord Abbett Growth Leaders Fund , which has more than quadrupled investors' money in nine years by investing in high-growth tech, consumer, and healthcare stocks. He's even more optimistic about the coming decade, reasoning that the combination of the "technology revolution" and low interest rates should keep a secular bull market going through 2030. He also says there's little reason to worry about the market dominance of Big Tech because companies like Microsoft and Amazon are innovating in ways that help other companies succeed. Click here to sign up for our weekly newsletter Investing Insider . Visit Business Insider's homepage for more stories . A lot of experts go back and forth between praising Big Tech and worrying that it is dangerously dominant — but Thomas O'Halloran is consistent in thinking the companies deserve their success. "These companies are the greatest companies the planet has ever seen," he said of Apple , Microsoft , Amazon , Alphabet , and Facebook . "I don't worry about it at all, the concentration.
   Bull of the Day: Guardant Health (GH)  2019/12/09 10:27:00 Zacks Investment Research
Bull of the Day: Guardant Health (GH)
   Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?  2019/12/03 16:30:19 Zacks Investment Research
Is (GH) Outperforming Other Medical Stocks This Year?
   How SoftBank’s Masayoshi Son became poorer by $6 bn  2019/11/06 03:20:35 The Economic Times India
By Pavel Alpeyev, Venus Feng and Takahiko HyugaMasayoshi Son is paying the price for bold bets on startups from WeWork to Uber Technologies Inc.The founder of Japan’s SoftBank Group Corp. has seen his net worth slide about $6 billion from its peak this year after his strategy of aggressively backing technology pioneers backfired. His fortune tumbled to roughly $13.8 billion as of Tuesday, according to the Bloomberg Billionaires Index, after peaking in July at about $20 billion.Son will give details of the damage on Wednesday when his Japanese conglomerate reports earnings, including likely writedowns for Uber and WeWork. The Vision Fund, its primary investment vehicle for startups, is said to be planning to swallow a charge of at least $5 billion. Some of that stems from the spectacular implosion of WeWork, the once-celebrated co-working company that SoftBank is now bailing out after systemic governance failures tanked its IPO attempt. The U.S. company, which raised money at a $47 billion valuation in January, was said to be valued at less than $8 billion in the rescue package.“Son has been through a number of ups and downs before, but it seems like these days he’s taking on more and more risk,” said Mitsushige Akino, an executive officer with Ichiyoshi Asset Management Co. in Tokyo. “What’s really spooking investors is that they don’t know if WeWork is just the tip of the iceberg for SoftBank’s trouble.”Uber and WeWork, once among the brightest stars in the SoftBank constellation, now number among its worst performers.
   Double Your Money (or More!) With This Ridiculously Cheap Dividend Payer  2019/11/04 12:39:07 The Motley Fool Canada
Gamehost (TSX:GH) shares could easily double if a few important things start going right.
   Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know  2019/10/30 21:50:11 Zacks Investment Research
In the latest trading session, Guardant Health (GH) closed at $70.96, marking a +0.45% move from the previous day.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ゲノミック・ヘルス GH Guardant Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)